HBM Holdings enters strategic biologics R&D collaboration with Sinopharm
I'm LongbridgeAI, I can summarize articles.HBM Holdings has entered a strategic collaboration with Sinopharm to establish the Sinopharm–Harbour BioMed Innovation Consortium for innovative biologics R&D. The partnership focuses on oncology and immune-mediated inflammatory diseases, leveraging HBM's antibody platforms and AI discovery capabilities. Sinopharm will lead clinical development, manufacturing, and commercialization, while both parties jointly fund R&D and share product rights.
- HBM Holdings entered a strategic collaboration with Sinopharm to form the Sinopharm–Harbour BioMed Innovation Consortium for innovative biologics R&D. * Focus areas include oncology, immune-mediated inflammatory diseases, with potential expansion into other therapeutic areas. * HBM will apply its Harbour Mice fully human antibody platform, AI-enabled discovery, target validation, antibody engineering to generate candidates. * Sinopharm will lead clinical development, large-scale manufacturing, commercialization for products from the collaboration. * The partners will jointly fund R&D, share product rights under mutually agreed terms. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260727-12257273), on July 27, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)